CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium Tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease
Overview
Authors
Affiliations
IFN-γ-producing CD4 T cells are required for protection against Mycobacterium tuberculosis (Mtb) infection, but the extent to which IFN-γ contributes to overall CD4 T cell-mediated protection remains unclear. Furthermore, it is not known if increasing IFN-γ production by CD4 T cells is desirable in Mtb infection. Here we show that IFN-γ accounts for only ~30% of CD4 T cell-dependent cumulative bacterial control in the lungs over the first six weeks of infection, but >80% of control in the spleen. Moreover, increasing the IFN-γ-producing capacity of CD4 T cells by ~2 fold exacerbates lung infection and leads to the early death of the host, despite enhancing control in the spleen. In addition, we show that the inhibitory receptor PD-1 facilitates host resistance to Mtb by preventing the detrimental over-production of IFN-γ by CD4 T cells. Specifically, PD-1 suppressed the parenchymal accumulation of and pathogenic IFN-γ production by the CXCR3+KLRG1-CX3CR1- subset of lung-homing CD4 T cells that otherwise mediates control of Mtb infection. Therefore, the primary role for T cell-derived IFN-γ in Mtb infection is at extra-pulmonary sites, and the host-protective subset of CD4 T cells requires negative regulation of IFN-γ production by PD-1 to prevent lethal immune-mediated pathology.
CD4 T cell dysfunction is associated with bacterial recrudescence during chronic tuberculosis.
Chang E, Cavallo K, Behar S bioRxiv. 2025; .
PMID: 39896548 PMC: 11785196. DOI: 10.1101/2025.01.22.634376.
Lyu J, Narum D, Baldwin S, Larsen S, Bai X, Griffith D Front Immunol. 2024; 15:1427559.
PMID: 39717773 PMC: 11663721. DOI: 10.3389/fimmu.2024.1427559.
Immune correlates of protection as a game changer in tuberculosis vaccine development.
Wang J, Fan X, Hu Z NPJ Vaccines. 2024; 9(1):208.
PMID: 39478007 PMC: 11526030. DOI: 10.1038/s41541-024-01004-w.
Cytokines in gingivitis and periodontitis: from pathogenesis to therapeutic targets.
Neurath N, Kesting M Front Immunol. 2024; 15:1435054.
PMID: 39253090 PMC: 11381234. DOI: 10.3389/fimmu.2024.1435054.
Immune checkpoint inhibitors in infectious disease.
King H, Lewin S Immunol Rev. 2024; 328(1):350-371.
PMID: 39248154 PMC: 11659942. DOI: 10.1111/imr.13388.